Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the

Diabetes Prevention Program Outcomes Study

Featured Article:

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

Diabetes Care Volume 35: 731-737

April, 2012

Study Objective

  •Metformin produced weight loss and delayed or prevented diabetes in the Diabetes Prevention Program (DPP) •Study examined its long-term safety and tolerability along with weight loss, and change in waist circumference during the DPP and its long-term follow-up

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* et al. Diabetes Care 2012;35:731-737

Study Design

• Randomized double-blind clinical trial of metformin or placebo in participants with IGT followed by a 7–8-year open-label xtension

 • Analysis of adverse events, tolerability, and effect of adherence

on change in weight and waist circumference

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* et al. Diabetes Care 2012;35:731-737

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* et al. Diabetes Care 2012;35:731-737

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* et al. Diabetes Care 2012;35:731-737

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* et al. Diabetes Care 2012;35:731-737

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* et al. Diabetes Care 2012;35:731-737

Conclusions

 •Metformin used for diabetes prevention is safe and well tolerated. Weight loss is related to adherence to metformin and is durable for at least 10 years of treatment

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP* et al. Diabetes Care 2012;35:731-737